Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the Multiethnic Cohort.

Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, Rosen HR, Setiawan VW.

Hepatology. 2019 Sep 25. doi: 10.1002/hep.30967. [Epub ahead of print]

PMID:
31553803
2.

Fibrosis Changes in the Placebo Arm of NASH Clinical Trials.

Altayar O, Noureddin N, Thanda Han MA, Murad MH, Noureddin M.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2387. doi: 10.1016/j.cgh.2019.05.016. No abstract available.

PMID:
31543242
3.

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI.

Expert Opin Investig Drugs. 2019 Sep 19:1-7. doi: 10.1080/13543784.2020.1668374. [Epub ahead of print]

PMID:
31519114
4.

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic.

Pandyarajan V, Gish RG, Alkhouri N, Noureddin M.

Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365.

5.

Pathogenesis of NASH: The Impact of Multiple Pathways.

Noureddin M, Sanyal AJ.

Curr Hepatol Rep. 2018 Dec;17(4):350-360. doi: 10.1007/s11901-018-0425-7. Epub 2018 Oct 31.

PMID:
31380156
6.

Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.

Mato JM, Alonso C, Noureddin M, Lu SC.

World J Gastroenterol. 2019 Jun 28;25(24):3009-3020. doi: 10.3748/wjg.v25.i24.3009. Review.

7.

Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis.

Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaat9284. doi: 10.1126/scitranslmed.aat9284.

PMID:
31189722
8.

Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, McCullough A, Alkhouri N.

Dig Dis Sci. 2019 Jun 11. doi: 10.1007/s10620-019-05700-9. [Epub ahead of print]

PMID:
31187324
9.

Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment.

Alkhouri N, Lawitz E, Noureddin M.

Hepatol Commun. 2019 Mar 28;3(5):605-613. doi: 10.1002/hep4.1342. eCollection 2019 May. Review.

10.

Liver Transplantation for Severe Alcoholic Hepatitis: Report of a Single Center Pilot Program.

Sundaram V, Wu T, Klein AS, Noureddin M, Kim IK, Todo T, Ayoub WS, Galloway C, Christianson AL, Nissen NN.

Transplant Proc. 2018 Dec;50(10):3527-3532. doi: 10.1016/j.transproceed.2018.08.057. Epub 2018 Sep 6.

PMID:
30577231
11.

Gα12 ablation exacerbates liver steatosis and obesity by suppressing USP22/SIRT1-regulated mitochondrial respiration.

Kim TH, Yang YM, Han CY, Koo JH, Oh H, Kim SS, You BH, Choi YH, Park TS, Lee CH, Kurose H, Noureddin M, Seki E, Wan YY, Choi CS, Kim SG.

J Clin Invest. 2018 Dec 3;128(12):5587-5602. doi: 10.1172/JCI97831. Epub 2018 Nov 12.

12.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA.

Gastroenterology. 2018 Nov;155(5):1463-1473.e6. doi: 10.1053/j.gastro.2018.07.027. Epub 2018 Jul 27.

13.

Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.

Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM.

Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul.

14.

Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD).

Noureddin M, Loomba R.

Aliment Pharmacol Ther. 2018 Aug;48(3):378-379. doi: 10.1111/apt.14819. No abstract available.

PMID:
29998503
15.

Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study.

Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, Noureddin M, Ayoub WS, Durazo F, Benhammou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S.

Hepatol Res. 2018 Dec;48(13):1108-1117. doi: 10.1111/hepr.13207. Epub 2018 Jul 30.

16.

Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.

Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):616-629.e26. doi: 10.1016/j.cgh.2018.06.011. Epub 2018 Jun 18. Review.

PMID:
29913275
17.

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.

Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN.

Am J Gastroenterol. 2018 Nov;113(11):1649-1659. doi: 10.1038/s41395-018-0088-6. Epub 2018 Jun 8.

PMID:
29880964
18.

A Rare Case of Lemierre-Like Syndrome: A Case Report and Literature Review.

Ibrahim J, Noureddin MB, Lootah A, Al Khalidi A, Ghatasheh G, Al Tatari H.

Case Rep Pediatr. 2018 Apr 1;2018:9613493. doi: 10.1155/2018/9613493. eCollection 2018.

19.

Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.

Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, Shen H, Yang J, Xiong T, Steggerda J, Liu Z, Noureddin M, Maldonado SS, Annamalai A, Seki E, Mato JM, Lu SC.

Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.

20.

Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.

Sundaram V, Jalan R, Ahn JC, Charlton MR, Goldberg DS, Karvellas CJ, Noureddin M, Wong RJ.

J Hepatol. 2018 Sep;69(3):617-625. doi: 10.1016/j.jhep.2018.04.016. Epub 2018 Apr 28.

PMID:
29709681
21.

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.

Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA.

World J Gastroenterol. 2018 Mar 21;24(11):1269-1277. doi: 10.3748/wjg.v24.i11.1269.

22.

Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease.

Amer J, Salhab A, Noureddin M, Doron S, Abu-Tair L, Ghantous R, Mahamid M, Safadi R.

Hepatol Commun. 2018 Feb 14;2(3):285-298. doi: 10.1002/hep4.1146. eCollection 2018 Mar.

23.

Role of Aramchol in steatohepatitis and fibrosis in mice.

Iruarrizaga-Lejarreta M, Varela-Rey M, Fernández-Ramos D, Martínez-Arranz I, Delgado TC, Simon J, Juan VG, delaCruz-Villar L, Azkargorta M, Lavin JL, Mayo R, Van Liempd SM, Aurrekoetxea I, Buqué X, Cave DD, Peña A, Rodríguez-Cuesta J, Aransay AM, Elortza F, Falcón-Pérez JM, Aspichueta P, Hayardeny L, Noureddin M, Sanyal AJ, Alonso C, Anguita J, Martínez-Chantar ML, Lu SC, Mato JM.

Hepatol Commun. 2017 Nov;1(9):911-927. doi: 10.1002/hep4.1107. Epub 2017 Oct 4.

24.

The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Shouhed D, Steggerda J, Burch M, Noureddin M.

Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):797-811. doi: 10.1080/17474124.2017.1355731. Epub 2017 Jul 21. Review.

PMID:
28712339
25.

Significance of platelet count in children admitted with bronchiolitis.

Al Shibli A, Alkuwaiti N, Hamie M, Abukhater D, Noureddin MB, Amri A, Al Kaabi S, Al Kaabi A, Harbi M, Narchi H.

World J Clin Pediatr. 2017 May 8;6(2):118-123. doi: 10.5409/wjcp.v6.i2.118. eCollection 2017 May 8.

26.

Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort.

Setiawan VW, Porcel J, Wei P, Stram DO, Noureddin N, Lu SC, Le Marchand L, Noureddin M.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1305-1307. doi: 10.1016/j.cgh.2017.02.038. Epub 2017 Mar 11. No abstract available.

27.

Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Han MA, Saouaf R, Ayoub W, Todo T, Mena E, Noureddin M.

Expert Rev Clin Pharmacol. 2017 Apr;10(4):379-390. doi: 10.1080/17512433.2017.1299573. Epub 2017 Mar 9. Review.

28.

Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gómez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Noureddin M, Falcón-Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM.

Gastroenterology. 2017 May;152(6):1449-1461.e7. doi: 10.1053/j.gastro.2017.01.015. Epub 2017 Jan 26.

29.

Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.

Fan W, Yang H, Liu T, Wang J, Li TW, Mavila N, Tang Y, Yang J, Peng H, Tu J, Annamalai A, Noureddin M, Krishnan A, Gores GJ, Martínez-Chantar ML, Mato JM, Lu SC.

Hepatology. 2017 Apr;65(4):1249-1266. doi: 10.1002/hep.28964. Epub 2017 Jan 31. Erratum in: Hepatology. 2017 Nov;66(5):1708.

30.

Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough?

Annamalai A, Harada MY, Chen M, Tran T, Ko A, Ley EJ, Nuno M, Klein A, Nissen N, Noureddin M.

J Am Coll Surg. 2017 Mar;224(3):276-282. doi: 10.1016/j.jamcollsurg.2016.11.005. Epub 2016 Nov 22.

31.

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, Noureddin M, Schiano TD, Siddiqui M, Sanyal A, Neuschwander-Tetri BA, Traber PG.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1183-1198. doi: 10.1111/apt.13816. Epub 2016 Oct 24.

32.

Promising therapies for treatment of nonalcoholic steatohepatitis.

Noureddin M, Zhang A, Loomba R.

Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28. Review.

33.

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation.

Khemichian S, Lee B, Kahn J, Noureddin M, Kim B, Harper T, Esmailian Y, Fong TL.

Transplant Direct. 2015 Jul 23;1(6):e21. doi: 10.1097/TXD.0000000000000531. eCollection 2015 Jul.

34.

Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.

Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M.

Hepatology. 2016 Dec;64(6):1969-1977. doi: 10.1002/hep.28677. Epub 2016 Jul 17.

35.

Hyponatraemia and neurological complications in children admitted with bronchiolitis.

Al Shibli A, Abukhater D, Al Kuwaiti N, Noureddin MB, Al Harbi M, Al Kaabi A, Al Kaabi S, Hamie M, Al Amri A, Narchi H.

Paediatr Int Child Health. 2016 Aug;36(3):175-80. doi: 10.1080/20469047.2016.1162390. Epub 2016 Apr 15.

PMID:
27079908
36.

Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Noureddin M, Anstee QM, Loomba R.

Aliment Pharmacol Ther. 2016 Jun;43(11):1109-23. doi: 10.1111/apt.13620. Epub 2016 Apr 8. Review.

37.

The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis.

Tana MM, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME, Noureddin M, Kleiner DE, Zhao X, Heller T, Hoofnagle JH.

Am J Clin Pathol. 2015 Oct;144(4):601-6. doi: 10.1309/AJCPQV4A7QAEEFEV.

38.

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.

Noureddin M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E, Liang TJ.

Genes Immun. 2015 Jul-Aug;16(5):321-9. doi: 10.1038/gene.2015.11. Epub 2015 May 28.

39.

Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.

Noureddin M, Rinella ME.

Clin Liver Dis. 2015 May;19(2):361-79. doi: 10.1016/j.cld.2015.01.012. Epub 2015 Mar 12. Review.

40.

Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Noureddin M, Mato JM, Lu SC.

Exp Biol Med (Maywood). 2015 Jun;240(6):809-20. doi: 10.1177/1535370215579161. Epub 2015 Apr 13. Review.

41.

MRI, CT scan, and ultrasound in the diagnosis of nonalcoholic fatty liver disease.

Noureddin M, Khoyilar C, Palmer SL.

J Clin Gastroenterol. 2015 Apr;49(4):351-2. doi: 10.1097/MCG.0000000000000281. No abstract available.

42.

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).

Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC).

Hepatology. 2015 Apr;61(4):1239-50. doi: 10.1002/hep.27647. Epub 2015 Feb 27.

43.

Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.

Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2014 Oct;60(4):1160-9. doi: 10.1002/hep.27092. Epub 2014 Aug 13.

44.

Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery.

Noureddin M, Gish R.

Curr Gastroenterol Rep. 2014 Jan;16(1):365. doi: 10.1007/s11894-013-0365-x. Review.

45.

Reply: To PMID 23703931.

Noureddin M, Wright EC, Ghany MG.

Hepatology. 2014 Apr;59(4):1651. doi: 10.1002/hep.26690. Epub 2014 Mar 5. No abstract available.

46.

Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.

Han H, Noureddin M, Witthaus M, Park YJ, Hoofnagle JH, Liang TJ, Rotman Y.

J Hepatol. 2013 Nov;59(5):957-63. doi: 10.1016/j.jhep.2013.07.004. Epub 2013 Jul 10. Erratum in: J Hepatol. 2014 Jun;60(6):1334-5.

47.

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner DE, Liang TJ, Ghany MG.

Hepatology. 2013 Nov;58(5):1548-57. doi: 10.1002/hep.26506. Epub 2013 Sep 30.

48.

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.

Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, Loomba R.

Hepatology. 2013 Dec;58(6):1930-40. doi: 10.1002/hep.26455. Epub 2013 Oct 17.

49.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN.

Hepatology. 2013 Nov;58(5):1644-54. doi: 10.1002/hep.26465. Epub 2013 Oct 2.

50.

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ.

Gut. 2014 Jan;63(1):161-9. doi: 10.1136/gutjnl-2012-303852. Epub 2013 Feb 8.

Supplemental Content

Loading ...
Support Center